Rapid Access Cancer Clinics: Evaluating Impact Beyond Timeliness

Rapid access cancer clinics have been implemented to address delays in the diagnosis and management of patients with suspected malignancy. The National Health Service (NHS) long term plan introduced the faster diagnosis standard (FDS), ensuring that patients are told whether they have cancer within a maximum of 28 days from referral [1]. The FDS is intended to reduce time to diagnosis, alleviate anxiety, minimize unwarranted variation, and provide a more patient-centered performance standard. Rapid access clinics aim to achieve similar goals by consolidating referral pathways and concentrating specialist expertise, potentially improving operational efficiency, diagnostic accuracy, and patient experience. Rapid access clinics can shorten the time to treatment initiation (TTI). Jeganathan and colleagues report a median time from referral to clinic assessment of 15 days, with weekly clinics reducing this interval to 14 days [2]. The median interval from specialist review to multidisciplinary team (MDT) discussion was only 5 days, indicating efficient integration of diagnostic findings. However, the median time from clinic review to treatment initiation was 41 days, representing a substantial delay in the pathway. As these values represent medians, more than half of patients experienced even longer delays. While early assessment and rapid MDT discussion are commendable, the prolonged interval to treatment represents a clear target for improvement. Although the overall median referral-to-treatment interval of 55 days falls within the NHS maximum target of 62 days, a substantial proportion of patients likely experienced delays beyond optimal timelines [3]. Direct comparison with national standards is challenging because Jeganathan et al. report median intervals rather than the proportion of patients meeting benchmark targets, and the time points used differ from those recommended by organizations such as the Cancer Council in Australia and the National Institute for Health and Care Excellence (NICE), which informs NHS standards [3, 4]. For example, the Cancer Council Optimal Care Pathway for Head and Neck Cancer recommends that surgery occur within 4 weeks of MDT discussion [5]. In contrast, Jeganathan et al. [2] report a median interval of 41 days from specialist clinic review to treatment initiation. Accounting for the reported 5-day median interval from clinic review to MDT discussion suggests an approximate median of 36 days from MDT discussion to treatment, indicating that the majority of patients likely did not meet this recommended target. However, faster treatment is not always a reliable surrogate for improved outcomes. Large population-based studies demonstrate that survival impacts of treatment delays are often modest and vary by cancer type and stage. In a SEER analysis of nearly one million patients with breast, lung, prostate, or colorectal cancers, Ang et al. [6] found that after adjusting for confounders, a TTI of 2–5 months was associated with a hazard ratio of only 1.02 compared with 0–1 month, representing just a 2% increase in mortality, despite statistical significance. Larger effects were seen only with TTI ≥ 10 months (HR 1.23), illustrating that small differences in time often have minimal clinical impact. Data from Cone et al. encompassing 2 241 706 patients with breast, prostate, non-small cell lung, and colon cancers, further highlight that the effect of treatment delays is highly variable. While all-stage prostate and breast cancers showed little association with TTI, higher-risk subgroups demonstrated modest effects, and colon and lung cancers exhibited the largest mortality differences [7]. For example, stage III colon cancer had a 5-year predicted mortality of 38.9% for TTI 61–120 days versus 47.8% for TTI 181–365 days, whereas high-risk prostate cancer showed minimal differences (12.8% vs. 14.1%). These findings underscore that survival consequences are context-dependent, influenced by tumor biology, stage, and disease aggressiveness. This heterogeneity is mirrored in head and neck cancer. Murphy et al. analyzed 51 655 patients from the National Cancer Data Base and found that treatment delays beyond 46–52 days were associated with worse overall survival, but the effect varied by site and stage [8]. Even in this large cohort, only a subset of patients experienced clinically meaningful differences, reinforcing that TTI alone is an imperfect measure of quality in head and neck oncology. From a diagnostic and operational perspective, Jeganathan's study reports interventions such as same-day ultrasound-guided FNA with immediate “in-room” cytopathology review (267 patients, 61%), same-day CT (163 patients, 37%), and same-week PET (113 patients, 25.9%) [2]. While these interventions appear patient-centered, they do not constitute robust or standardized measures of patient experience. Simply reporting that these procedures were performed does not capture whether patients' anxiety, satisfaction, or overall burden of care were meaningfully reduced. Furthermore, qualitative statements such as the FNA diagnosis being “promptly communicated” to the surgeon are not very informative, providing little measurable insight into the patient experience or timeliness of decision-making. FNA performance in this cohort demonstrated a sensitivity of 89.9% and specificity of 80.0% [2]. While good, specificity is lower than results reported in larger series. For example, Rammeh et al. [9] evaluated 1262 FNAs from head and neck masses and reported a sensitivity of 92%, specificity of 94.4%, and overall accuracy of 93.5% compared with histology. This suggests that rapid access clinics can reliably facilitate tissue diagnosis, but diagnostic yield may improve with standardized protocols or larger patient volumes. Implementing a rapid access clinic in the public healthcare system is a complex undertaking. It requires dedicated clinic time, radiology and pathology support, and close MDT coordination. In Australia, where most outpatient specialist care occurs in private rooms, financial incentives to support such models are limited. Further, Australia lacks NHS-mandated targets for TTI and supportive implementation frameworks to achieve such targets [4]. Without clear evidence of improved survival or broad quality gains, the primary justification may be patient-centered: reducing financial and logistical burdens, minimising fragmented appointments, and improving the diagnostic experience. In this regard, Jeganathan and colleagues need to be congratulated for “tacking up the slack” and providing what is presumably a considerable cost-saving to patients. They demonstrate that a rapid access neck lump clinic is operationally feasible within a public tertiary center. However, the potential value of rapid access clinics likely lies more in enhancing patient experience and reducing costs, aligning with the goals of the NHS FDS to reduce anxiety, provide clarity, and create more patient-centered care [1]. Sadly, these metrics are lacking in this study, and future evaluation should focus on measurable patient-centered outcomes rather than solely on treatment timelines. Jonathan R. Clark AM: writing – original draft. The author declares no conflicts of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.